Capricor Therapeutics Bolsa (NASDAQ: CAPR)

Últimas noticias sobre Capricor Therapeutics (NASDAQ:CAPR) Bolsa

Capricor Therapeutics

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index falling over 200 points on Wednesday.
The Dow traded down 0.59% to 41,960.39 while the NASDAQ rose 0.03% to 18,079.66. The S&amp;P 500 also fell, dropping, 0.16% to 5,723.63.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41022196/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-with-over-4-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Utilities shares jumped by 0.7% on Wednesday.
In trading on Wednesday, energy shares fell by 1.9%.
Top Headline
Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August, compared to a revised 10.3% gain in July.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares shot up 37% to $12.44. Maxim Group and Oppenheimer increased price targets on the stock.</li>
<li>Shares of Eightco Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) got a boost, surging 46% to $3.6250. Eightco Holdings expects to deliver revenues of $100 million for 2025.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 13% to $0.1056 after the company announced it secured $1.25 million in financing and requested an FDA type A meeting to address the clinical hold on CER-1236.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) shares dropped 56% to $0.1585 after the company announced it filed for Chapter 11 bankruptcy.</li>
<li>Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) were down 37% to $2.3510 after the company reported worse-than-expected fourth-quarter EPS results.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) was down, falling 18% to $7.70 after the company announced that the Company&#8217;s Board of Directors has determined to disband the Special Committee.</li>
</ul>
Commodities In commodity news, oil traded down 2.6% to $69.69 while gold traded up 0.3% at $2,685.50.
Silver traded down 0.9% to $32.135 on Wednesday, while copper fell 0.1% to $4.4880.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.11%, Germany's DAX fell 0.41% and France's CAC 40 fell 0.50%. Spain's IBEX 35 Index fell 0.38%, while London's FTSE 100 fell 0.17%.
Producer prices in Spain declined by 1.3% year-over-year in August compared to a revised 1.6% decline in the previous month. The consumer confidence indicator in France climbed to 95.1 in September from 92.5 in the prior month.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 falling 0.19%, Hong Kong's Hang Seng Index jumping 0.68%, China's Shanghai Composite Index gaining 1.16% and India's BSE Sensex gaining 0.30%.
The People's Bank of China cut its one-year policy loan rate by 30bps to 2.0%.
Economics
<ul>
<li>U.S. building permits increased by 4.6% to an annual rate of 1.470 million in August.</li>
<li>U.S. mortgage applications rose by 11% from the prior week during the week ending Sept. 20, compared to a 14.2% increase in the previous week.</li>
<li>Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August of 2024, compared to a revised 10.3% gain in the prior month. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41021427/accenture-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurat">Accenture Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

CAPR

CERO

OCTO

SFIX

VTNR

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 50 points on Wednesday.
The Dow traded down 0.35% to 42,060.13 while the NASDAQ rose 0.39% to 18,145.24. The S&amp;P 500 also rose, gaining, 0.06% to 5,736.28.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41022196/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-with-over-4-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Information technology shares jumped by 0.9% on Wednesday.
In trading on Wednesday, energy shares fell by 1.1%.
Top Headline
Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August, compared to a revised 10.3% gain in July.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares shot up 20% to $ 10.87. Maxim Group and Oppenheimer increased price targets on the stock.</li>
<li>Shares of Eightco Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) got a boost, surging 66% to $4.14. Eightco Holdings expects to deliver revenues of $100 million for 2025.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 20% to $0.1122 after the company announced it secured $1.25 million in financing and requested an FDA type A meeting to address the clinical hold on CER-1236.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertex Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTNR#NASDAQ">VTNR</a>) shares dropped 65% to $0.1272 after the company announced it filed for Chapter 11 bankruptcy.</li>
<li>Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) were down 35% to $2.4401 after the company reported worse-than-expected fourth-quarter EPS results.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) was down, falling 18% to $7.71 after the company announced that the Company&#8217;s Board of Directors has determined to disband the Special Committee.</li>
</ul>
Commodities In commodity news, oil traded down 1.4% to $70.57 while gold traded up 0.5% at $2,689.20.
Silver traded up 0.1% to $32.43 on Wednesday, while copper rose 0.5% to $4.5120.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.20%, Germany's DAX fell 0.54% and France's CAC 40 fell 0.66%. Spain's IBEX 35 Index fell 0.31%, while London's FTSE 100 fell 0.22%.
Producer prices in Spain declined by 1.3% year-over-year in August compared to a revised 1.6% decline in the previous month. The consumer confidence indicator in France climbed to 95.1 in September from 92.5 in the prior month.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 falling 0.19%, Hong Kong's Hang Seng Index jumping 0.68%, China's Shanghai Composite Index gaining 1.16% and India's BSE Sensex gaining 0.30%.
The People's Bank of China cut its one-year policy loan rate by 30bps to 2.0%.
Economics
<ul>
<li>U.S. building permits increased by 4.6% to an annual rate of 1.470 million in August.</li>
<li>U.S. mortgage applications rose by 11% from the prior week during the week ending Sept. 20, compared to a 14.2% increase in the previous week.</li>
<li>Sales of new single-family houses in the U.S. fell by 4.7% from the prior month to an annualized rate of 716,000 in August of 2024, compared to a revised 10.3% gain in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/41021427/accenture-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurat">Accenture Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Earnings

Crude Oil Down Over 1%; Stitch Fix Shares Plummet

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares increased by 28.2% to $5.16 during Wednesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 26.07% to $2.74. The market value of their outstanding shares is at $4.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock moved upwards by 20.59% to $0.11. The company's market cap stands at $5.8 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 19.78% to $10.9. The market value of their outstanding shares is at $385.1 million. </li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) stock increased by 14.51% to $21.0. The company's market cap stands at $252.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares increased by 12.7% to $1.27. The market value of their outstanding shares is at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares declined by 15.6% to $0.14 during Wednesday's regular session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 12.97% to $2.55. The market value of their outstanding shares is at $11.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares declined by 11.66% to $2.88. The company's market cap stands at $4.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 10.74% to $0.48. The market value of their outstanding shares is at $1.3 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares decreased by 10.65% to $19.84. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares declined by 10.64% to $0.41. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BBLG

CRBP

ERNA

FTRE

OGEN

SNTI

STSS

TNON

VTAK

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday.
Shares of Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) rose sharply during Wednesday's session after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">target from $20 to $24</a>.
Hewlett Packard Enterprise shares jumped 5.5% to $19.92 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) shares jumped 26.2% to $8.37.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) gained 21.8% to $11.09. Maxim Group and Oppenheimer increased price targets on the stock.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 15.5% to $3.9750. Northland Capital Markets analyst Mike Grondahl initiated coverage on Cipher Mining with an Outperform rating and announced a price target of $6.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) jumped 14% to $5.61.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) shares jumped 12.9% to $64.52 after Oppenheimer raised its price target on the stock from $66 to $70. The stock is also moving on continued strength following strong third-quarter earnings and guidance yesterday.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) gained 10.8% to $4.98.</li>
<li>Biohaven Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NASDAQ">BHVN</a>) surged 9% to $49.09. Biohaven recently announced its study of Troriluzole for the treatment of spinocerebellar ataxia in achieved the primary endpoint.</li>
<li>Flutter Entertainment plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NASDAQ">FLUT</a>) surged 8.3% to $246.99. Flutter Entertainment outlined long-term growth plan and up to $5 billion share repurchase program authorization.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 8% to $8.20. The company announced its electron low Earth orbit mission on Friday Sept. 20th.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 7.6% to $13.77.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) climbed 7.5% to $5.11.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) gained 7% to $40.26.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 5.4% to $14.13.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 4% to $23.73.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose 3% to $124.44. The company's CEO Jensen Huang adopted a Rule 10b5-1 trading plan earlier this year. According to a Barron's report, the Nvidia CEO has completed selling the maximum number of shares under the plan several months early.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>

Intraday Update

AIXI

BHVN

CIFR

FLUT

INTC

MNSO

NVDA

POET

PRGS

RKLB

RZLV

UPST

Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday

Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and raises the price target from $15 to $43.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $43

Maxim Group analyst Jason McCarthy maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and raises the price target from $12 to $25.

Maxim Group Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

On Tuesday, major U.S. indices closed higher, with the Dow Jones Industrial Average gaining 0.2% to reach 42,208.22, the S&amp;P 500 rising 0.25% to 5,732.93, and the Nasdaq climbing 0.6% to 18,074.52.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
NVIDIA shares surged by 3.97% to close at $120.87. The stock&#8217;s intraday high and low were $121.8 and $115.38 respectively, with a 52-week range of $140.76 &#8211; $39.23. The uptick followed reports that CEO Jensen Huang had <a href="https://www.benzinga.com/news/24/09/41010963/nvidia-stock-is-ripping-higher-tuesday-whats-going-on">completed selling company stock</a> under a trading plan several months early.
Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)
Alibaba shares rose by 7.88% to close at $97.19 after China's central bank announced plans to slash banks' reserve requirement ratio. The stock&#8217;s intraday high and low were $97.5 and $94.4 respectively, with a 52-week range of $97.5 &#8211; $66.63. The company&#8217;s shares rose after China&#8217;s central bank announced a 50 basis point cut to banks&#8217; reserve requirement ratio, <a href="https://www.benzinga.com/government/24/09/41004045/whats-going-on-with-chinese-stocks-alibaba-nio-xpeng-li-auto-on-tuesday">signaling potential economic support</a> and boosting investor confidence in Chinese tech stocks.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40971260/trumps-historic-bitcoin-transaction-ethereum-co-founder-backs-trump-over-harris-for-crypto?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Historic Bitcoin Transaction, Ethereum Co-Founder Backs Trump Over Harris For Crypto, Gamestop Customer&#8217;s Bitcoin Windfall, And More: This Week In Cryptocurrency</a>
Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>)
Capricor shares soared by 52.43% to close at $9.10 following the company&#8217;s announcement of intent to <a href="https://www.benzinga.com/news/24/09/41005497/why-capricor-therapeutics-stock-is-soaring-tuesday">file a biologics license application</a> for the full approval of Deramiocel. The stock&#8217;s intraday high and low were $9.24 and $7.42 respectively, with a 52-week range of $9.24 &#8211; $2.68. 
Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)
Taiwan Semi shares climbed by 4.13% to close at $181.97 after the company secured an additional $7.5 billion infusion into its Arizona unit. The stock&#8217;s intraday high and low were $182.78 and $177.05 respectively, with a 52-week range of $193.47 &#8211; $84.02. TSMC shares rose after the company secured government approval for an <a href="https://www.benzinga.com/government/24/09/41007184/taiwan-semi-secures-7-5b-boost-for-arizona-expansion-aims-for-advanced-chip-production-report">additional $7.5 billion investment</a> into its Arizona unit, bolstering its U.S. expansion efforts and investor confidence.
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares rose by 1.71% to close at $254.27. The stock&#8217;s intraday high and low were $257.19 and $249.05 respectively, with a 52-week range of $271 &#8211; $138.8. The surge was fueled by optimism concerning third-quarter deliveries outperformance. Meanwhile, Gary Black <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40995280/tesla-bull-dampens-enthusiasm-regarding-1010-robotaxi-event-but-heres-what-would-ta">expressed skepticism</a> about the Oct. 10 Robotaxi event being a major catalyst, the fund manager emphasized potential growth from a sub-$30K compact car launch.
Photo by WHYFRAME on Shutterstock
Prepare for the day&#8217;s trading <a href=""Premarket">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41000017/how-to-earn-500-a-month-from-nvidia-stock?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Earn $500 A Month From Nvidia Stock</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

BABA

TSLA

Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $40 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the treatment of <a href="https://www.benzinga.com/pressreleases/24/09/g40999783/capricor-therapeutics-announces-intent-to-file-biologics-license-application-for-full-approval-of-">Duchenne muscular dystrophy cardiomyopathy</a>.
What To Know: Capricor said it determined its intent to file a BLA following recent meetings with the&nbsp;U.S. Food and Drug Administration.
Based on those meetings, Capricor plans to commence the filling in October, seeking full approval of deramiocel for the treatment of DMD-cardiomyopathy with full submission expected by the end of the year.
The company noted that the filing will be based on existing cardiac data from the Phase 2 HOPE-2 and HOPE-2 Open Label Extension trials. Capricor said it plans to combine Cohorts A and B of the Phase 3 clinical trial to serve as a post-approval study. 
&#8220;There are currently no approved therapies for DMD cardiomyopathy, which is the leading cause of death in those with Duchenne. Based on the strength of our cardiac data, combined with the FDA&#8217;s commitment to advancing therapeutics for the treatment of rare diseases, we are seeking approval for the cardiomyopathy associated with DMD and will look to expand the label for skeletal muscle myopathy post-approval,&#8221; said Linda Marbán, CEO of Capricor Therapeutics.
&#8220;Deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. Based on the totality of evidence of the safety and efficacy data deramiocel has shown, we believe this is the best path forward to potential approval.&#8221;
<a href="http://benzinga.com/quote/capr">Capricor shares</a> are now up more than 55% over the past week. The stock has been in the spotlight since the company signed a <a href="https://www.benzinga.com/general/biotech/24/09/40899024/exclusive-capricor-therapeutics-inks-european-expansion-commercialization-pact-for-lead-asset-wit">European expansion deal </a>with Nippon Shinyaku. Several analysts have raised price targets on the stock since. Here&#8217;s a look at all of the analyst updates over the past week.
<ul>
<li>HC Wainwright &amp; Co. analyst Joseph Pantginis reiterated Capricor Therapeutics with a Buy and maintained a price target of&nbsp;$40.</li>
</ul>
<ul>
<li>Maxim Group analyst Jason McCarthy reiterates Capricor Therapeutics with a Buy and maintained a price target of&nbsp;$12.</li>
</ul>
<ul>
<li>Oppenheimer analyst Leland Gershell maintained Capricor Therapeutics with an Outperform and raised the price target from&nbsp;$14&nbsp;to&nbsp;$15.</li>
</ul>
<ul>
<li>Cantor Fitzgerald analyst Kristen Kluska reiterated Capricor Therapeutics with an Overweight and maintained a price target of&nbsp;$8.</li>
</ul>
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/biotech/24/09/40899024/exclusive-capricor-therapeutics-inks-european-expansion-commercialization-pact-for-lead-asset-wit">EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm</a>
CAPR Price Action: Capricor shares were up 27.1% at $7.63 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Why Capricor Therapeutics Stock Is Soaring Tuesday

WIIM

Capricor Therapeutics shares are trading higher after the company announced intent to file a biologics license application for the full approval of Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy.

-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- &nbsp;
-Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy-
-Rolling Submission Planned to Commence in October 2024-
-Internal GMP Manufacturing Established to Support BLA and Commercialization-
-Investor Webcast Today at 8:30 a.m. ET-
SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Dn3dPseyoYpJ2ydS9_fKGSY-L8y3j-58USJTWl-wU8dEA89PRS2JOkAnKJH6HgHxdaGntPImf1dAz10xwns5wWVF-ZkWxrG06hwj8W1ppJwm2PvCg47N6tUBYJpNjbU7XS0hd4gSdWmh8IMvOyGDntkraCOIdeb3sopV9B8ltkAflERhFEgZ-cOYB1pUfS5ZLkQMHm1eaJzMqxKEqbLfCNWU4f8b3VresJn-vaFF3zxYWk3KnleejbWgj8uh5dJg75izbevazWgAZXmJqhdVow==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file a Biologics License Application (BLA) based on existing cardiac and natural history data for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.

Biotech

General

Capricor Therapeutics Announces Intent To File Biologics License Application For Full Approval Of Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy

Oppenheimer analyst Leland Gershell reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and maintains $15 price target.

Oppenheimer Reiterates Outperform on Capricor Therapeutics, Maintains $15 Price Target

<a href="https://www.globenewswire.com/Tracker?data=afIWGkduhoVWw5lazkmLDNF728FYi3fnOKz7m1KZFvViHJUntsxkVMWD9K-hYRaToZml2BsyGyge69LMPna48J12i2G6N3Xzc9SLUZvypAgDzPilFPOI8Cz4TXDDVCARtrGuLITwCQK1YlysMr-YdxsCYK0h1oIk9QURo5KyuJTXDaE_MUryiucdqKTfwVDeQyUTkENQoc8kaYSVXqyqnxcxzeTopQG5OTI5F4IqjVtebgRnY3m_nX10YTfqvDZoMHSkvc30szNezP2ztLjTig==">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administration (FDA). &nbsp;
Webcast Details
Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-717-1738 (domestic/toll-free) or 1-646-307-1865 (international) and reference the conference ID: 62574. Participants can use guest dial-in numbers above and be answered by an operator or click <a href="https://www.globenewswire.com/Tracker?data=5AKI7jB4QKUvue1lnb96fqjZ8j8GZ9V1GHZq_NN2fwCH5svNZRxBkzXgDK1zmo8eojdc3fDbDpmDahf7nxGvI9Gfoy4kfIC1AxVcgdvH0Og=">here</a> for instant telephone access. To participate via webcast, please click <a href="https://www.globenewswire.com/Tracker?data=5AKI7jB4QKUvue1lnb96fq1Zut4R0yEvi9ff6fGJhAcHs4IIHXaNrmUU8h-cxoq4GHOTrEt83z4yixgN-OUjEJrHc7J8vk4bXojG1TinhRuGXmkyE6DBubcSMxd56HjyaDC2lYDN0mrQ-yTYxyEYag==">here</a> to view the slides. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the <a href="https://www.globenewswire.com/Tracker?data=nFxBPfkAeaG_eZnMr2-UIo9QhrWhZNi7oPMLSSQjyOFzFyVOhMcUJwcQeiA-gOasuxefW8y_qOLX9FnMMGyoVA==">Company's website</a>.

Events

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update On September 24, 2024 At 8:30 a.m. ET

In the latest quarter, 5 analysts provided ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.0, along with a high estimate of $40.00 and a low estimate of $8.00. Surpassing the previous average price target of $22.80, the current average has increased by 0.88%.
<img src="https://www.benzinga.com/files/images/story/2024/1726851677_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Capricor Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Capricor Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Breaking Down Capricor Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Capricor Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.38%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Capricor Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -276.97%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -73.49%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -25.08%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Capricor Therapeutics's debt-to-equity ratio is below the industry average at 0.16, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $8 price target.

Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $8 Price Target

Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Outperform and raises the price target from $14 to $15.

Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $15

Maxim Group analyst Jason McCarthy reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $12 price target.

Maxim Group Reiterates Buy on Capricor Therapeutics, Maintains $12 Price Target

Capricor Therapeutics shares are trading higher after the company signed a binding term sheet with Nippon Shinyaku for the European expansion and commercialization of Deramiocel for the treatment of Duchenne muscular dystrophy.

Tuesday, Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) entered into a binding term sheet with&nbsp;Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the commercialization and distribution in Europe of Capricor's lead asset, deramiocel, for <a target="_blank" href="https://www.benzinga.com/quote/capr" rel="noreferrer noopener">Duchenne muscular dystrophy (DMD)</a>.
DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles.
In June, Capricor Therapeutics released three-year results from the ongoing HOPE-2 open-label extension&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39160101/capricor-therapeutics-reports-3-year-efficacy-results-from-hope-2-open-label-extension-study-of-c" rel="noreferrer noopener">study with CAP-1002</a> in boys and young men with DMD.
According to the results, patients treated with CAP-1002 continued to show benefits after three years of treatment compared to an external comparator dataset of <a target="_blank" href="https://www.benzinga.com/news/24/06/39166716/whats-going-on-with-capricor-therapeutics-stock-tuesday" rel="noreferrer noopener">similar DMD patients</a>.
The company also announced the long-term benefits of deramiocel, showing increased cardiac function based on <a target="_blank" href="https://www.benzinga.com/news/24/06/39554236/whats-going-on-with-capricor-therapeutics-stock-friday" rel="noreferrer noopener">several different measures</a>.
The potential transaction covered by the term sheet is similar to the existing Commercialization and Distribution Agreements with Nippon Shinyaku in the United States and Japan, with an opportunity for global product reach.
In addition, Nippon Shinyaku has agreed to purchase approximately $15 million of Capricor common stock at a 20% premium to the 60-day VWAP.
Nippon Shinyaku will purchase around 2.79 million common shares at $5.36 per share.
Capricor will be responsible for developing and manufacturing deramiocel for potential approval in the European Union, the U.K., and several other countries in the region.
Nippon Shinyaku will be responsible for the sales and distribution of deramiocel in those territories.
Capricor will also receive an upfront payment of $20 million, additional development and sales-based milestone payments of up to $715 million, and a double-digit share of product revenue.
The potential milestones from the combined agreements now total approximately $1.5 billion.
"With the addition of the upfront payment and equity investment, we will be able to extend our runway into 2026 and be well-positioned to advance toward potential approval of deramiocel in the United States and beyond. Furthermore, these funds will provide necessary capital for commercial launch preparations, manufacturing scale-up, and product development for Europe," said Linda Marbán, Capricor's CEO.
The company plans to start FDA rolling submission in the <a target="_blank" href="https://www.benzinga.com/news/24/06/39278531/whats-going-on-with-capricor-therapeutics-stock-tuesday" rel="noreferrer noopener">2024 third quarter</a>.
Price Action: CAPR stock is trading higher by 6.55% to $4.69 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40888884/intel-missed-out-on-playstation-6-chip-deal-to-amd-report" target="_blank" rel="noreferrer noopener">Intel Missed Out on PlayStation 6 Chip Deal to AMD: Report</a>.</li>
</ul>

Health Care

Contracts

Market-Moving Exclusives

Exclusives

EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm

Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel

An announcement from Capricor Therapeutics ( ($CAPR) ) is now available. Capricor Therapeutics has struck a pivotal deal with Nippon Shinyaku for t...

Capricor Therapeutics Secures Lucrative European Partnership

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report) and keeping the price targe...

Buy Rating Affirmed for Capricor Therapeutics Amidst Expanded Partnership and Regulatory Advancements

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCa...

Capricor Therapeutics Poised for Growth with Expanded Deramiocel Partnership and Positive Phase 3 Outlook

Japan's Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and up to $715 million in milestones, plus royalties.

Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy

Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The associated pric...

Buy Rating Affirmed for Capricor Therapeutics on Promising DMD-cardiomyopathy Treatment Prospects

Capricor surges on plans to seek FDA approval for lead asset

Capricor Therapeutics ( ($CAPR) ) has shared an announcement. Capricor Therapeutics is set to file a Biologics License Application for deramiocel, ...

Capricor Therapeutics Aims for DMD Treatment Approval and Expansion

Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off

NPNKF

NPPNY

SFOSF

SRPT

Press Releases

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Comments

Capricor Therapeutics

Noticias

Últimas noticias sobre Capricor Therapeutics (NASDAQ:CAPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL